These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 15696142)

  • 21. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 22. A taxing dilemma.
    Jacobs T
    Nat Biotechnol; 2005 Oct; 23(10):1219. PubMed ID: 16211056
    [No Abstract]   [Full Text] [Related]  

  • 23. My worst biotech investment.
    Jacobs T
    Nat Biotechnol; 2006 Apr; 24(4):401. PubMed ID: 16601718
    [No Abstract]   [Full Text] [Related]  

  • 24. Biotech holds steady in Q4.
    Mitchell P
    Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
    [No Abstract]   [Full Text] [Related]  

  • 25. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 26. Finding new life in health stocks.
    Armour LA
    Fortune; 1997 Sep; 136(6):289-90, 292, 294. PubMed ID: 10173398
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 28. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 29. Gary Pisano.
    Pisano G
    Nat Biotechnol; 2011 Mar; 29(3):183. PubMed ID: 21390002
    [No Abstract]   [Full Text] [Related]  

  • 30. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 31. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 32. The margin of safety.
    Jacobs T
    Nat Biotechnol; 2002 Dec; 20(12):1191. PubMed ID: 12454663
    [No Abstract]   [Full Text] [Related]  

  • 33. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 34. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 35. 25 top health care stocks. Will they lead the next market boom?
    Kane L
    Med Econ; 2001 Apr; 78(7):126-8, 133-6, 140-2. PubMed ID: 11368040
    [No Abstract]   [Full Text] [Related]  

  • 36. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 37. Stelios Papadopoulos.
    Papadopoulos S
    Nat Biotechnol; 2011 Mar; 29(3):184. PubMed ID: 21390003
    [No Abstract]   [Full Text] [Related]  

  • 38. Public companies get creative in raising finance.
    Hodgson J
    Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
    [No Abstract]   [Full Text] [Related]  

  • 39. US venture capital for biotechnology.
    Dibner MD; Trull M; Howell M
    Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
    [No Abstract]   [Full Text] [Related]  

  • 40. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.